All In MedTech

Device Trial Radar · NCT02528552

Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO

A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradome™ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia

Last checked: Nov 20, 2026Latest source record: Dec 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

80

Planned (sponsor's estimate)

Start

Aug 2015

Primary completion

Oct 2016

Study completion Dec 2016

Sponsor

Lead sponsor
Theradome, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 19, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a prospective, randomized double-blind, multi-center study to evaluate the efficacy of low level laser therapy over-the-counter at home device Theradome LH80 PRO, compared to SHAM for promoting hair growth in males diagnosed with androgenetic alopecia, and a usability study to assess subject ability to self-assess hair loss and understanding use of the device.

Conditions

  • Androgenetic Alopecia

Interventions

  • LH80 PRODevice

  • Sham DeviceDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hair growthTime frame: 26 weeks

1 more outcomes with a free account

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Axis Clinical Tirals

    Los Angeles, California

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.